Comparison of Intravenous Nefopam and Tramadol for Postoperative Analgesia in Laparoscopic Cholecystectomy Surgery Patients: A Randomized Controlled Trial

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

TCTR

Registry ID

TCTR20230704006

Enrollment

Registered

2023-07-04

Start date

2023-07-01

Completion date

Unknown

Last updated

2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Laparoscopic cholecystectomy surgery patients Nefopam, Tramadol, postoperative pain, laparoscopic cholecystectomy

Interventions

Tramadol intravenous injection for standard postoperative analgesia,Nefopam intravenous infusion for experimental postoperative analgesia

No Intervention Drug,Experimental Drug

Tramadol,Nefopam

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Laparoscopic cholecystectomy surgery paitients 2. Elective or emergency surgery 3. American Society of Anesthesiologist physical status classification I-II

Exclusion criteria

Exclusion criteria: 1. Recieved analgesic drug or sedative drug within 24 hours preoperatively 2. Opiois or alcohol abuse 3. High risk for postoperative nausea and vomiting 4. Underlying disease: epilepsy, gaucoma, psychiatric problems 5. Allergy medications used in research 6. Pregnancy or breastfeeding patient

Design outcomes

Primary

Measure	Time frame
Postoperative pain at 0.5, 3, 6, 12 and 24 hours after end of the operation Numeric rating scale	—

Secondary

Measure	Time frame
Number of drug adverse effects within 24 hours after end of the intervention Patient reported drug adverse effects using a questionnaire interview	—

Countries

Thailand

Contacts

Public ContactChompoonik Jiemjitpolchai

Sawanpracharak Hospital

nongnaiy@gmail.com0896928002

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026